Eplerenone for Central Serous Chorioretinopathy

* The goal of the study is to examine the short-term effects and safety of a systemic anti-aldosterone medication, eplerenone, in a small group of patients with central serous chorioretinopathy (CSCR). * There is currently no standard treatment or therapy for either acute or chronic CSCR, a potentially debilitating eye disease. * There is evidence in both animals and humans that high blood serum corticosteroid levels can cause or worsen CSCR or findings similar to CSCR in the choroid and retina * Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR * The investigators' aim is to evaluate a standardized dose of eplerenone in a controlled prospective fashion for both acute and chronic CSCR. * The study consists of taking a standard dose of eplerenone, 50mg once daily, for 1 month * Over the course of the month, patients will be monitored for side effects, as well as visual and anatomical response to the medication